Last Updated on December 17, 2024 by The Health Master
Warning letter
Indoco Remedies, a prominent Indian pharmaceutical company with a global presence, has recently received a warning letter from the United States Food and Drug Administration (USFDA) regarding its manufacturing facilities in Verna, Goa.
This development follows a previous Official Action Indicated (OAI) status assigned to the same facility in October 2024.
The warning letter underscores the ongoing challenges Indoco faces in meeting USFDA’s stringent Current Good Manufacturing Practice (CGMP) standards.
Background: The USFDA Inspection and OAI Status
The USFDA conducted an inspection of Indoco’s Plant II & Plant III facility, located at L 32, 33 – 34 Verna Industrial Estate Area, Verna, Goa, India, between July 16, 2024, and July 26, 2024.
Following this inspection, the facility was designated with an OAI status on October 11, 2024.
This classification signifies that the USFDA found significant violations of its regulations.
The recent warning letter reinforces the USFDA’s concerns and requires Indoco to take immediate and comprehensive corrective actions.
Indoco’s Response and Commitment to Compliance
In response to the warning letter, Indoco Remedies issued a statement emphasizing its commitment to working closely with the USFDA to resolve the identified issues.
The company reiterated its dedication to enhancing compliance on an ongoing basis and assured that it would cooperate fully with the USFDA to address the concerns promptly.
Indoco also highlighted its commitment to maintaining CGMP quality standards across all its facilities and affirmed that it continues to supply products from the Goa facility to meet its obligations to customers and patients in the United States.
Key Takeaways:
- Indoco Remedies received a USFDA warning letter for its Goa manufacturing facility.
- The facility had previously received an OAI status following a USFDA inspection.
- Indoco has expressed its commitment to working with the USFDA to resolve the issues.
- The company continues to supply products from the facility to meet its obligations.
Bullet Points:
- Facility: Indoco Remedies Plant II & Plant III, Verna, Goa, India
- Inspection Period: July 16, 2024 – July 26, 2024
- OAI Status Issued: October 11, 2024
- Warning Letter Issued: [Insert date of warning letter if available]
- Indoco’s Response: Commitment to cooperate with USFDA and enhance compliance.
-
What does a USFDA warning letter mean?
A USFDA warning letter is a formal notice from the FDA to a regulated company regarding significant violations of FDA regulations. It requires the company to take corrective actions to address the identified issues.
-
What is OAI status?
OAI (Official Action Indicated) status is a classification assigned by the FDA after an inspection, indicating that significant objectionable conditions or practices were found that may lead to regulatory action.
-
What are CGMPs?
CGMPs (Current Good Manufacturing Practices) are regulations enforced by the FDA to ensure the quality and safety of pharmaceutical products.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issues warning letters to two Chinese firms over data integrity concerns
USFDA issues warning letter to Zydus for injectables unit at Jarod
USFDA issues warning letter to Eugia Pharma subsidiary of Aurobindo
USFDA issues warning letter to Brassica Pharma, Maharashtra
USFDA issues warning letter to Sun Pharma for Dadra Unit
USFDA issues warning letter to Laurus Labs for Andhra Facility
Karnataka creates unified Food and Drug Administration (FDA)
CDSCO to undergo massive Expansion in the coming year
Key Notes on Revised Schedule M: Point No. 9 – Production under Loan License
Action against sale of habit-forming drugs without prescription: Tamil Nadu
Gujarat’s Medical Device Park: A Game-Changer for India’s Healthcare Sector
Key Notes on Revised Schedule M: Point No. 8 – Change Control
Drug recall: Aurobindo Pharma, Glenmark, Zydus recall Drugs
Hospitals can’t force Patients to buy medicines from their in house Medical Store
FDA Haryana Organizes Workshop for Chemists: Yamunanagar
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
